Plus Therapeutics to Present Data from ReSPECT-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (GlobeNewswire) - Aug 13, 2021 - "Plus Therapeutics, Inc...announced it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECT™ clinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021."
P1 data • Glioma • Oncology
|